Terminal

2025-11-12 21:13
CEO – James Passin
CFO – Kenneth Kovan
Auditors – DMCL
Global Market Trading
[stock_market_widget type="ticker-markets" template="basic" color="#FFFFFF" markets="AMS,ASX,ATHEX,BCBA,BIST,BOVESPA,BME,BMV,BRU,BSE,COL,COP,CSE,EPA,EUREX,FSX,HEL,HKEX,IDN,ISE,JSE,KRX,LSE,MOEX,MTA,MYX,NASDAQ,NSE,NYSE,NZX,OSE,PSI,RIG,SET,SGX,SIX,SSE,STO,TADAWUL,TAL,TASE,TSE,TSX,TWSE,VIL,VSE,XETRA,XBER,XDUS,XHAM,XMUN,XSTU" animation="true" style="font-size: 17;" speed="350" direction="left" pause="true"]
[stock_market_widget type="inline-label" template="basic5" color="#5679FF" assets="BVAXF" api="yf"]
[stock_market_widget type=”list-companies” template=”basic” assets=”BVAXF” fields=”logo_name,symbol,description,industry,sector,website” api=”yf”]
Ready to Publish & File?
Click the button below to dispatch your order!
Fill out my online form.



Service Note!
Please text 305-332-2873 for all Immediate or after hour submission 10pm EST – 6am EST.

NOTE: To avoid any delays in the dissemination of your press release, Please ensure that you have provided the City/State of Origin, Date/Time, Contact Information (Name/Phone/Email) and Source of the press release along with an email id for us to include that in the press release: Company or Media contact as follows: Note that a name, email id, and a phone number are mandatory for media contact details according to our editorial guidelines

Your Investor/Media Dashboard
Explore Latest Market Updates on markets-headlines. Share Your Company News & Filings, Analyze Global Equities, Stay Informed with Todays Market News.
[stock_market_widget type=”chart” template=”line” assets=”BVAXF” range=”1mo” interval=”1d” price_field=”close” api=”yf” border_width=”3″ tension=”0″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true”]
[stock_market_widget type=”table-history” template=”black-background” color=”#5679FF” assets=”BVAXF” fields=”open,high,low,close,date” range=”1mo” interval=”1d” pagination=”true” rows_per_page=”5″ sort_direction=”asc” alignment=”left” api=”yf”]

BioVaxys Technology Corp.
BVAXF
Biotechnology
Healthcare
biovaxys.com
646 452 7054
BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms. It develops BVX-0320, a SARS-CoV-2 vaccine; BVX-1021, a vaccine for the strain of coronavirus that causes SARS1; and BVX-0918, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, a novel diagnostic platform to identify a T-cell immune response to the presence of SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions. It has a bioproduction agreement with WuXi Biologics Limited to produce SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; and research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320. BioVaxys Technology Corp. is based in Vancouver, Canada.


Portfolio Tracker

Supported Exchanges = LSE, TSX, NYSE, NASDAQ
Supported Currencies = USD, GBP

Need Content Support?
Use MH virtual bot to assist creating your content!